Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Updates Plavix Label, Leaves Effient With Clear Advantage

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.

You may also be interested in...



Best of the Blog, IN VIVO, November 2009

A selection of our favorite blog posts from November 2009 about stories not covered elsewhere in this issue of IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).

AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy

AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards

Best of the Blog, IN VIVO, November 2009

A selection of our favorite blog posts from November 2009 about stories not covered elsewhere in this issue of IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).

Related Content

Topics

UsernamePublicRestriction

Register

PS068758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel